BioClinica acquires Synowledge
Adds capabilities in pharmacovigilance and regulatory technology, data analysis and business process management
BioClinica, a specialist clinical trials services and technology provider, has acquired Synowledge for an undisclosed sum.
The transaction will enable BioClinica to expand its offering into the growing drug safety and regulatory business process outsourcing market.
Headquartered in Miami, FL, US, Synowledge, which employs 500 people, specialises in pharmacovigilance, regulatory affairs and information technology services to support biopharmaceutical companies with recording, analysing and reporting adverse drug events.
'This acquisition extends BioClinica's solutions into an important new area for our customers,' said BioClinica's President and Chief Executive John Hubbard.
'Synowledge is a highly regarded provider that biopharmaceutical corporations trust to manage the critical process of monitoring and reporting adverse drug events. Its capabilities complement our deep scientific expertise and technology-enabled services that support our customers in developing and bringing new drugs to market as safely and efficiently as possible.'
Sankesh Abbhi, who founded Synowledge in 2006, added: 'We are very pleased to become part of BioClinica. Our companies share a deep commitment to serving our customers and supporting their goals through highly specialised expertise and tailored solutions. Together, we offer customers a broader set of services and increased access to resources that support their overall drug development process.'
Effective immediately, Abbhi will serve as Senior Vice President and Head of Global Safety and Regulatory Solutions. He will report to Mukhtar Ahmed, President of BioClinica's eClinical Solutions Division.